Country
Germany
Boehringer Ingelheim GmbH is to pay €1.18 billion to acquire NBE-Therapeutics GmbH, a Swiss developer of antibody-drug conjugates (ADCs), in order to expand its portfolio of drugs targeting difficult-to-treat solid tumours.
Full text available to subscribers only. Click here for information on subscribing to MedNous.